Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly: A Prospective, Longitudinal, Multicenter, Observational Study in Germany
- Conditions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 200
- Registration Number
- NCT06743035
- Locations
- 🇩🇪
Onkologisches Studienzentrum Dr. med. Ingo Zander & Dr. med. Eyck von der Heyde, Hannover, Niedersachsen, Germany
Ripretinib (QINLOCK®) According to Current SmPC
- Conditions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 100
- Registration Number
- NCT06619275
- Locations
- 🇩🇪
Praxis für interdisziplinäre Onkologie und Hämatologie, Freiburg, Germany
Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - an Observational Study
- Conditions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 100
- Registration Number
- NCT06607302
- Locations
- 🇩🇪
Caritas Krankenhaus Bad Mergentheim, Bad Mergentheim, Germany
🇩🇪Onkologisches Versorgungszentrum Berlin MVZ, Berlin, Germany
Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC
- Conditions
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 100
- Registration Number
- NCT06181734
- Locations
- 🇩🇪
Praxis für interdisziplinäre Onkologie & Hämatologie, Freiburg, Germany
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 2950
- Registration Number
- NCT06043011
- Locations
- 🇩🇪
Praxis für Interdisziplinäre Hämatologie und Onkologie, Freiburg, Germany
Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 100
- Registration Number
- NCT05954780
- Locations
- 🇩🇪
Gemeinschaftspraxis für Hämatologie und Onkologie GbR, Ravensburg, Baden-Württemberg, Germany
🇦🇹Medizinische Universität Wien, Universitätsklinik für Innere Medizin I, Wien, Austria
Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO)
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 50
- Registration Number
- NCT05517265
- Locations
- 🇩🇪
Prof. Dr. Fenchel & Dr. Winkler MVZ Träger GbR, Saalfeld, Thüringen, Germany
Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 605
- Registration Number
- NCT05326308
- Locations
- 🇩🇪
Lübecker Onkologische Schwerpunktpraxis, Lübeck, Schleswig-Holstein, Germany
🇦🇹Universitätsklinikum Salzburg, Klinik für Innere Medizin III, Salzburg, Austria
Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv)
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 96
- Registration Number
- NCT05284591
- Locations
- 🇩🇪
Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Hessen, Germany
Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 300
- Registration Number
- NCT05253911
- Locations
- 🇩🇪
Universitätsklinikum Essen, Innere Klinik (Tumorforschung), Essen, Northrhine-Westphalia, Germany
🇦🇹Medizinische Universität Wien, Innere Medizin I, Hämatologie und Onkologie, Vienna, Austria